Investors are buzzing about Imunon Inc (NASDAQ: IMNN) as it shows potential for explosive growth in the biotechnology sector. With a remarkable price percent change of
178.99, the stock has captured the attention of those looking for high returns. The company’s recent price action indicator of 1.07 suggests that momentum is on the rise, making it an enticing option for savvy investors. As the market continues to evolve, Imunon could very well be on the brink of a significant breakthrough that rewards those who get in early.
Major Takeaways
The asset utilization indicator measures the revenue generated for every dollar of assets a company reports. Imunon Inc has an asset utilization ratio of 0.57%, indicating that the company earns $0.005703 for each dollar of assets. An increasing asset utilization ratio suggests that Imunon Inc is becoming more efficient in utilizing its assets for daily operations.
The successful prediction of Imunon
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Imunon Inc, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Imunon based on Imunon hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Imunon's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Imunon's related companies.
Watch out for price decline
Please consider monitoring Imunon on a daily basis if you are holding a position in it. Imunon is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Imunon stock to be traded above the $1 level to remain listed. If Imunon stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Use Technical Analysis to project Imunon expected Price
Imunon technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Imunon technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Imunon trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Imunon Gross Profit
Imunon Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Imunon previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Imunon Gross Profit growth over the last 10 years. Please check Imunon's
gross profit and other
fundamental indicators for more details.
Breaking it down a bit more
The company reported the previous year's revenue of 125
K. Net Loss for the year was (19.51
M) with profit before overhead, payroll, taxes, and interest of 500
K.
| 2021 | 2022 | 2023 | 2024 (projected) |
Total Operating Expenses | 21.5M | 25.4M | 20.3M | 16.9M | Cost Of Revenue | 702.9K | 731.6K | 720.0K | 684.0K |
Total Revenue Breakdown
Imunon Total Revenue yearly trend continues to be very stable with very little volatility. Total Revenue is likely to drop to about 118.8
K. Total Revenue usually refers to the total amount of income generated by the sale of goods or services related to the company's primary operations. At this time, Imunon's Total Revenue is very stable compared to the past year.
| 2010 | 74,006 |
| 2011 | 2 Million |
| 2012 | 500,000 |
| 2023 | 125,000 |
| 2024 | 118,750 |
In the world of investing, the phrase "buy low, sell high" often echoes through the minds of traders. Imunon Inc (NASDAQ: IMNN) has recently garnered attention as it navigates the tumultuous waters of the biotechnology sector. With a current market capitalization of $11.19 million and a price-to-sales ratio of 17.94X, the stock's valuation may appear steep, especially considering its revenue of only $125,000 and gross profit of $500,000. However, the company holds significant cash reserves of $42.11 million, providing a cushion against its current losses and a potential pathway for future growth. Investors should also note the potential upside of 11.3, indicating that there may still be room for appreciation, but the high probability of bankruptcy at 96% raises serious concerns about the company's long-term viability.
Another 3 percent roll up for Imunon
Imunon Inc. has shown notable resilience in the market, with its stock variance reduced to 513.06, indicating tighter price fluctuations and potential stabilization in investor sentiment. This decline in variance suggests the stock may be entering a more predictable trading range, appealing to both cautious and opportunistic investors. As the company advances its innovative therapies, this 3% increase reflects growing confidence in its future prospects, making it an intriguing option for those looking to capitalize on upward momentum. As of July 31, Imunon has a downside deviation of 4.85, a risk-adjusted performance of 0.0851, and a market risk-adjusted performance of 0.875.
Analyzing Imunon's technical indicators can help identify patterns that may predict future price movements.Investing in Imunon Inc. (IMNN) presents a compelling opportunity, especially given the current analyst consensus, which is a strong buy. With a naive expected forecast value of
3.06 and a valuation market value of
3.32, the stock appears to be undervalued compared to its potential upside. Analysts have set a target price estimated value of
12.5, indicating significant room for growth. While there are risks, including a possible downside price of 0.0332, the overall outlook suggests that Imunon could be a lucrative addition to your portfolio as it continues to develop its innovative therapies..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Imunon Inc. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
